Individuals infected with the human immunodeficiency virus (HIV), the etiologic agent of acquired immunodeficiency syndrome (AIDS), often show symptoms associated with reactivation of Epstein-Barr virus (EBV). In this study, we show that exposure of EBV-positive B lymphocytes to HIV-I in vitro induc
Scid mouse model of epstein-barr virus-induced lymphomagenesis of immunodeficient humans
✍ Scribed by David T. Purtilo; Kerstin Falk; Samuel J. Pirruccello; Hirokazu Nakamine; Kimberly Kleveland; Jack R. Davis; Motohiko Okano; Yuichi Taguchi; Warren G. Sanger; Kirk W. Beisel
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- French
- Weight
- 1010 KB
- Volume
- 47
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Immunodeficient humans are at very high risk of developing Epstein‐Barr virus (EBV)‐induced lymphomagenesis. Severe combined immunodeficient mice (SCID) have been shown to develop lymphoproliferative disease (LPD) following transfer of peripheral blood leukocytes (PBL) with latent EBV. To study mechanisms of lymphomagenesis, we compared results of engraftment of PBL from normal donors and immunodeficient donors with X‐linked lymphoproliferative disease (XLP). Graft‐versus‐host disease (GVHD) developed in 6 of 10 SCID mice 4 to 8 weeks following transfer of PBL from normal donors. In contrast, none of 9 mice engrafted with PBL from XLP patients with T‐cell defects showed GVHD. LPD developed in mice regardless of the immune competence of the donors. The expression of EBV‐encoded proteins, results of immunophenotyping, and karyotyping of the LPD lesions revealed lethal oligoclonal LPD owing to transfer of latent EBV in B cells in mice engrafted with PBL from seropositive donors. Polyclonal LPD developed in mice engrafted with PBL from seronegative patients which were infected with B95‐8 virus 6 weeks after transfer of the cells. This model is useful for investigating mechanisms of EBV‐induced LPD in immunodeficient patients.
📜 SIMILAR VOLUMES
## Abstract The efficiency of transformation of human lymphocytes after infection with Epstein‐Barr virus (EBV) was determined in fractionated and non‐fractionated preparations derived from 16 human cord blood samples and two blood samples from adult donors. The transformation efficiency of macroph
## Abstract Cellular immune responses to Epstein‐Barr Virus (EBV)‐associated antigens play an important role in the control of EBV‐immortalized B lymphocytes. The nature of the antigens that serve as targets for these responses remains largely unknown. The purpose of the experiments reported here w
## Abstract Epstein‐Barr virus (EBV) reactivation is more likely to occur in immunocompromised patients with subsequent higher susceptibility to EBV‐associated lymphoproliferations. In contrast to transplant recipients, limited data are available concerning the EBV load in HIV‐infected patients, wi